Evidence map›Paper›PMID 31028182›Full record

ReviewIn vivo (Athens, Greece)

The Role of ARID1A in Endometrial Cancer and the Molecular Pathways Associated With Pathogenesis and Cancer Progression.

Chrisavgi Toumpeki, Anastasios Liberis, Ioannis Tsirkas, Theodora Tsirka, Sofia Kalagasidou, Lola Inagamova, Xanthoula Anthoulaki, Georgios Tsatsaris, Emmanuel N Kontomanolis

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Somatic and germline mutations in endometrial cancer.Journal of medicine and life · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. GermlineJCO precision oncology · 2022
    Article
  17. Prevalence ofCancers · 2022
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Chrisavgi ToumpekiDepartment of Obstetrics and Gynecology, Democritus University of Thrace, Alexandroupolis, Greece.
Anastasios LiberisSecond Department of Obstetrics and Gynecology, Hippokration General Hospital, Thessaloniki, Greece.
Ioannis TsirkasDepartment of Obstetrics and Gynecology, Democritus University of Thrace, Alexandroupolis, Greece.
Theodora TsirkaDepartment of Molecular Biology and Genetics, University of Thrace, Alexandroupolis, Greece.
Sofia KalagasidouDepartment of Obstetrics and Gynecology, Bodosakio General Hospital of Ptolemaida, Ptolemaida, Greece.
Lola InagamovaDepartment of Obstetrics and Gynecology, Democritus University of Thrace, Alexandroupolis, Greece.
Xanthoula AnthoulakiDepartment of Obstetrics and Gynecology, Democritus University of Thrace, Alexandroupolis, Greece.
Georgios TsatsarisDepartment of Obstetrics and Gynecology, Democritus University of Thrace, Alexandroupolis, Greece.
Emmanuel N KontomanolisDepartment of Obstetrics and Gynecology, Democritus University of Thrace, Alexandroupolis, Greece mek-2@otenet.gr.
Democritus University of Thrace · GRUniversity Hospital of Alexandroupolis · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

AT-rich interaction domain 1A gene (ARID1A) encodes for a subunit of the switch/sucrose non-fermentable (SWI/SNF) complex, a chromatin remodeling complex, and it has been implicated in the pathogenesis of various cancer types. In this review, we discuss how ARID1A is linked to endometrial cancer and what molecular pathways are affected by mutation or inhibition of ARID1A. We also discuss the potential use of ARID1A not only as a prognostic biomarker, but also as a target for therapeutic interventions.

Indexed as

Gene Expression Regulation, NeoplasticSignal TransductionAnimalsDisease ProgressionDisease SusceptibilityDNA-Binding ProteinsEndometrial NeoplasmsEpigenesis, GeneticFemaleHumansMutationNuclear ProteinsTranscription FactorsARID1A protein, humanDNA-Binding ProteinsNuclear ProteinsTranscription FactorsARID1Aendometrial cancermolecular pathwaysreview

Identifiers

PMID31028182
PMCPMC6559907
OpenAlexW2940975864

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.